Sarepta Therapeutics (SRPT) EBIT (2010 - 2026)

Sarepta Therapeutics' EBIT history runs 17 years deep, the most recent figure standing at $358.4 million for Q1 2026.

• In Q1 2026, EBIT rose 219.32% year-over-year to $358.4 million; the TTM figure through Mar 2026 stood at -$41.0 million (up 65.05% YoY), while the FY2025 annual figure was -$699.8 million, down 420.88% from the prior year.
• EBIT was $358.4 million for Q1 2026 at Sarepta Therapeutics, up from -$411.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $358.4 million in Q1 2026 to a low of -$411.6 million in Q4 2025.
• Historically, EBIT has averaged -$54.5 million across 5 years, with a median of -$86.9 million in 2022.
• Biggest YoY gain for EBIT was 16587.45% in 2025; the steepest drop was 960.58% in 2025.
• A 5-year view of EBIT shows it stood at -$106.8 million in 2022, then soared by 123.05% to $24.6 million in 2023, then jumped by 556.57% to $161.7 million in 2024, then slumped by 354.56% to -$411.6 million in 2025, then soared by 187.09% to $358.4 million in 2026.
• The last three EBIT figures came in at $358.4 million (Q1 2026), -$411.6 million (Q4 2025), and -$103.4 million (Q3 2025), per Business Quant data.